Skip to main content

ViraxClear Signs Letter of Intent and Secures Purchase Order for Infrared Thermometers to North Africa

Written by Customer Service on . Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, May 22, 2020 (GLOBE NEWSWIRE) — Global Care Capital Corp. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture Shanghai Biotechnology Devices Ltd. (“SBD”) has on May 20th, 2020, finalized a Letter Of Intent (LOI) with Phyto Pharma Ltd (“Phyto”), for the supply of 5,000 FDA Registered and CE marked infrared thermometer units (“Thermometers”) for sale in North Africa, with a Purchase Order signed for the value of US$ 125,000 for the 5,000 units.James Foster, CEO of ViraxClear, states that, “The sudden surge in numbers of novel coronavirus (COVID-19) cases has caused nations across the globe to take steps to stop the spread. Ever since the outbreak of the deadly disease, there has been a need to routinely check temperatures. The temperature in such cases is not checked using a mercury thermometer. To do this, offices, airports, malls and hotels are using forehead thermometers, also known as infrared thermometers. These thermometers check the temperature by sensing the infrared energy radiated by the body and are used to detect body temperature in case of fever, one of the symptoms of coronavirus.”“Securing FDA Registered and CE marked product from a reputable manufacturer represents a significant opportunity for ViraxClear and its distribution partners.”LOI for ThermometersViraxClear has signed an LOI and purchase order to distribute 5,000 infrared thermometers for sale to existing Morocco based distribution partner Phyto for the region of North Africa. An initial purchase order for 5,000 units has been signed, with a value of US$125,000, which will be fulfilled in the coming days. Phyto will be responsible for funding the shipping costs of the thermometers. This represents the first sale of a new product for ViraxClear, which primarily focuses on COVID-19 Antibody Test Kits. Accessing the North African market is an important first step in the roll out of infrared thermometers and other medical devices.Supply Agreement between SBD and VenusViraxClear has secured supply of the infrared thermometers through Hong Kong based Venus Health Consulting Limited (“Venus”) for the Guofengtai brand of thermometers. Guofengtai is manufactured by China based Jiangxi GuoFeng Medical Equipment Co. Ltd (“Jiangxi”).The thermometers do not require contact with a person and can swiftly measure temperature from 1cm-5cm from the forehead. These are particularly useful for use in public places like a hotel, airport, factory or office and with demand increasing as people begin to return to their normal lives and places of work. These are battery-operated, handy and easy to use thermometers, which do not require any trained technicians. Whilst they are by no means definitively accurate in the detection of COVID-19, they are widely being used across the world to detect potential symptomatic COVID-19 carriers.The infrared thermometers are also an important component of the ViraxClear Employee Protection Equipment (EPE) Kits that it planning to launch next month: A scientifically curated kit of key protective equipment, which will be crucial in creating conditions for an acceptable level of safety in the workplace.About ViraxClearViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.About Global CareGlobal Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.GLOBAL CARE CAPITAL CORP.: Company Contact: Alex Somjen, President & CEOasomjen@globalcarecapital.comNeither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.